Replimune’s RP1 is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response.

A drug long used to fight cancer may soon take on a very different role. Researchers at the University of Illinois Chicago ...

Replimune (REPL) stock crashed 19% after FDA rejected RP1 melanoma treatment for second time, citing trial design issues.

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous ...

Replimune (REPL) stock plunged 19% after FDA issued second rejection of RP1 melanoma immunotherapy, citing inadequate trial ...

Sexually transmitted diseases (STDs), also known as sexually transmitted infections (STIs), continue to pose a major global ...

Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly ...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN ® (fluocinolone acetonide intravitreal ...

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...

Patients received an initial intratumoral injection of RP1 with up to 7 additional doses every 2 weeks, plus 240 mg nivolumab ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will present new research at the American Association for Cancer Research (AACR) Annual Meeting, highlighting ...